AGT and Alzheimer disease: Remarkably, during the 14 d Ang II administration, 87.50% (21/24) of CCDC80−/− mice experienced AD following Ang II treatment—primarily in the ASC and suprarenal abdominal aorta (AA)—compared with 8.33% (2/24) of WT mice (p < 0.0001) (Figure2A,D); 62.50% (15/24) of male CCDC80−/− mice died of AD and rupture (Figure 2C,D) compared with 8.33% (2/24) of male WT mice.